Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biocept Inc

(NASDAQ: BIOC)
Add to Portfolio
-0.26 (-48.15%)
as of 14:14 EST

Last 0.28
Change -0.26 (-48.15%)
Open 0.25
Prev. Close 0.54
Today's Range
0.24
0.28
52wk Range
0.24
3.72
Volume 29,244,628
Avg Volume 2,257,483
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
BIOC -48.15% -65.25% -72.45%
DJIA -0.36% +4.22% +14.61%
S&P 500 -0.29% +6.07% +19.31%

Key Statistics

Annual EPS -2.67
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 11,810
Weighted Alpha -75.97
Standard Deviation -4.33
Profit Margin 3.63%
Beta 1.71

Growth Rates

YTD -67.00%
1-Year -47.58%
3-Year -97.98%
5-Year -99.79%

Opinion

Sell Hold Buy

Recent Headlines

Biocept Announces Pricing of $10.0 Million

PR Newswire via COMTEX - 09:15AM EST
Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-f(full story)
BIOC: 0.28 (-0.26)

Biocept's Liquid Biopsy CTC Testing for Breast Cancer

PR Newswire via COMTEX - Tue Dec 03, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that cli(full story)
BIOC: 0.28 (-0.26)

Biocept Announces the Launch of its Liquid Biopsy Test

PR Newswire via COMTEX - Thu Nov 21, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the comm(full story)
BIOC: 0.28 (-0.26)

Biocept Reports Third Quarter 2019 Financial Results

PR Newswire via COMTEX - Wed Nov 13, 04:05PM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 0.28 (-0.26)

Biocept Announces CE IVD Marks and Availability of its

PR Newswire via COMTEX - Thu Nov 07, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conf(full story)
BIOC: 0.28 (-0.26)